These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29846589)

  • 1. Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART.
    Nouchi A; Nguyen T; Valantin MA; Simon A; Sayon S; Agher R; Calvez V; Katlama C; Marcelin AG; Soulie C
    J Antimicrob Chemother; 2018 Aug; 73(8):2141-2146. PubMed ID: 29846589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.
    Gantner P; Morand-Joubert L; Sueur C; Raffi F; Fagard C; Lascoux-Combe C; Salmon D; Amiel C; Lambert-Niclot S; Fofana DB; Viard JP; Fafi-Kremer S; Rouzioux C; Avettand-Fenoel V; Ghosn J
    J Antimicrob Chemother; 2016 Mar; 71(3):751-61. PubMed ID: 26676973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of pretreatment minority HIV-1 reverse transcriptase inhibitor-resistant variants by ultra-deep sequencing has a limited impact on virological outcomes.
    Su B; Zheng X; Liu Y; Liu L; Xin R; Lu H; Huang C; Bai L; Mammano F; Zhang T; Wu H; Sun L; Dai L
    J Antimicrob Chemother; 2019 May; 74(5):1408-1416. PubMed ID: 30668734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
    Armenia D; Di Carlo D; Calcagno A; Vendemiati G; Forbici F; Bertoli A; Berno G; Carta S; Continenza F; Fedele V; Bellagamba R; Cicalini S; Ammassari A; Libertone R; Zaccarelli M; Ghisetti V; Andreoni M; Ceccherini-Silberstein F; Bonora S; Di Perri G; Antinori A; Perno CF; Santoro MM
    J Antimicrob Chemother; 2017 Mar; 72(3):855-865. PubMed ID: 27999048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study.
    Charpentier C; Montes B; Perrier M; Meftah N; Reynes J
    J Antimicrob Chemother; 2017 Oct; 72(10):2831-2836. PubMed ID: 29091218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.
    Hayashida T; Hachiya A; Ode H; Nishijima T; Tsuchiya K; Sugiura W; Takiguchi M; Oka S; Gatanaga H
    J Antimicrob Chemother; 2016 Oct; 71(10):2760-6. PubMed ID: 27330069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
    Lambert-Niclot S; Allavena C; Grude M; Flandre P; Sayon S; Andre E; Wirden M; Rodallec A; Jovelin T; Katlama C; Calvez V; Raffi F; Marcelin AG
    J Antimicrob Chemother; 2016 Aug; 71(8):2248-51. PubMed ID: 27231280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The RT M184V resistance mutation clearance in the reservoir is mainly related to CD4 nadir and viral load zenith independently of therapeutic regimen type.
    Teyssou E; Soulie C; Fauchois A; Palich R; Nouchi A; Sayon S; Abdi B; Wirden M; Katlama C; Pourcher V; Marcelin AG; Calvez V
    J Antimicrob Chemother; 2024 Jul; 79(7):1673-1676. PubMed ID: 38804140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
    Geretti AM; Conibear T; Hill A; Johnson JA; Tambuyzer L; Thys K; Vingerhoets J; Van Delft Y;
    J Antimicrob Chemother; 2014 Apr; 69(4):1090-7. PubMed ID: 24284781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An unusual case of underlying rilpivirine resistance in an antiretroviral-naïve man with AIDS.
    Skalweit MJ
    Int J STD AIDS; 2016 Dec; 27(14):1346-1349. PubMed ID: 27074792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
    Loubet P; Charpentier C; Visseaux B; Borbor A; Nuta C; Adu E; Chapplain JM; Baysah M; Tattevin P; Yazdanpanah Y; Descamps D
    J Antimicrob Chemother; 2015; 70(6):1881-4. PubMed ID: 25698771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
    Charpentier C; Lee GQ; Rodriguez C; Visseaux B; Storto A; Fagard C; Molina JM; Katlama C; Yazdanpanah Y; Harrigan PR; Descamps D
    J Antimicrob Chemother; 2015 Jul; 70(7):2090-6. PubMed ID: 25755001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
    Lapadula G; Calabresi A; Castelnuovo F; Costarelli S; Quiros-Roldan E; Paraninfo G; Ceresoli F; Gargiulo F; Manca N; Carosi G; Torti C
    Antivir Ther; 2008; 13(4):601-5. PubMed ID: 18672539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
    Teeranaipong P; Sirivichayakul S; Mekprasan S; Ohata PJ; Avihingsanon A; Ruxrungtham K; Putcharoen O
    PLoS One; 2016; 11(4):e0154221. PubMed ID: 27120449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Resistance profile of rilpivirine].
    Imaz A; García F; di Yacovo S; Llibre JM
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.